Patient Satisfaction with AUSTEDO XR: A survey of 209 patients with tardive dyskinesia (TD) revealed that over 94% experienced movement improvement after treatment with AUSTEDO XR, with 89% expressing high satisfaction and 96% finding the medication easy to take.
Impact on Quality of Life: Patients reported enhanced social and emotional well-being due to reduced movements, with more than 77% agreeing that their improved condition led to greater comfort in social settings.
TEVA
$30.13+Infinity%1D
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TEVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.790
Low
28.00
Averages
29.25
High
32.00
Current: 29.790
Low
28.00
Averages
29.25
High
32.00
BofA
Buy
maintain
$29 -> $32
2025-12-09
Reason
BofA
Price Target
$29 -> $32
2025-12-09
maintain
Buy
Reason
BofA raised the firm's price target on Teva to $32 from $29 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.
Goldman Sachs
Matt Dellatorre
Buy
maintain
$28 -> $31
2025-12-08
Reason
Goldman Sachs
Matt Dellatorre
Price Target
$28 -> $31
2025-12-08
maintain
Buy
Reason
Goldman Sachs analyst Matt Dellatorre raised the firm's price target on Teva to $31 from $28 and keeps a Buy rating on the shares. The recently published IRA-negotiated price for Austedo, which will go into effect in 2027, was better than expected, and management has reiterated their FY27+ guidance for the product, the analyst tells investors in a research note. Goldman sees the company as capable of long-term mid-single digit EBITDA growth, driven by both topline execution and margin expansion, and no major upcoming losses-of-exclusivity.
Barclays
Overweight
initiated
$35
2025-12-08
Reason
Barclays
Price Target
$35
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of Teva with an Overweight rating and $35 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
Scotiabank
initiated
$35
2025-12-04
Reason
Scotiabank
Price Target
$35
2025-12-04
initiated
Reason
Scotiabank initiated coverage of Teva with an Outperform rating and $35 price target.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
